MARS Bioimaging and MediLumine Announce Partnership

Mars Bioimaging and MediLumine announce a partnership to develop applications for life science research and jointly announce the success of a pilot study using MediLumine’s contrast agents and the MARS color x-ray imaging system. 

In this study, the MARS scanner simultaneously identified and quantified three MediLumine contrast agents, Fenestra VC, Mvivo Au, and Mvivo BIS in a phantom with vials of the contrast agents.  The different contrast agents can be visualized in 3D and assigned different colors based on the ability of MARS technology to detect the differences in attenuation slopes and k-edge jumps. MediLumine and MARS will now work jointly to develop applications and related technical resources to facilitate applications for contrast enhanced color X-ray imaging.

Anthony Butler – MBI, President Medical

I’m really excited about this partnership as it combines the power of MARS quantitative imaging with the MediLumine’s functional contrast agents. The combination of the two technologies greatly increases the opportunity for novel molecular imaging for pre-clinical researchers.

Stephen Marchant – MediLumine, CEO

Working with MARS Bioimaging unlocks the potential of color x-ray imaging by providing a means to visualize disease in ways not yet imagined. Contrast enhanced color x-ray imaging will become a powerful tool in understanding human diseases and advancing drug discovery programs internationally.

About MediLumine Inc.

MediLumine is committed to providing high quality instruments, reagents and accessories to support preclinical imaging programs in the life sciences.  MediLumine’s PRISM™ series of in vivo imaging systems are designed for preclinical monitoring of physiological changes in living systems for therapeutic discovery research in academia and pharmaceutical industries.  MediLumine’s micro-CT contrast agents (Fenestra and Mvivo) provide image enhancement for various applications allowing scientists to monitor progression of functional liver diseases, visualize tumors, track cells in vivo and perform preclinical angiography.  For more information refer to

Share This Story, Choose Your Platform!